Khalil, Salem H <br/><br/>
Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.  [electronic resource] 

 -  Genetic testing and molecular biomarkers  Feb 2010 
 - 67-74 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1945-0257 
<br/><br/><label>Standard No.: </label>10.1089/gtmb.2009.0126  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Base Sequence<br/>Benzamides<br/>Biomarkers, Tumor--genetics<br/>Child<br/>Child, Preschool<br/>DNA Primers--genetics<br/>DNA, Neoplasm--genetics<br/>Drug Resistance, Neoplasm<br/>Female<br/>Fusion Proteins, bcr-abl--genetics<br/>Genes, abl<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Piperazines--therapeutic use<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Retrospective Studies<br/>Saudi Arabia<br/>Treatment Outcome<br/>Young Adult